Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jim Cassidy

Showing results (21-30 of 49) with videos related to

Pageof 5
Sort By:
Lancet (London, England)|June 28, 2002
Is the NICE process flawed?Jim Cassidy, John Bridgewater, Paul Mainwaring, et al.
Journal of Hazardous Materials|December 7, 2007
Corporate crisis management managing a major crisis in a chemical facilitySteve Marwitz, Neil Maxson, Bill Koch, et al.
Family Practice|July 12, 2002
Striking the right balance in colorectal cancer care--a qualitative study of rural and urban patientsNorma S C Bain, Neil C Campbell, Lewis D Ritchie, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 22, 2005
Significant effect of capecitabine on the pharmacokinetics and pharmacodynamics of warfarin in patients with cancerRoss Camidge, Bruno Reigner, Jim Cassidy, et al.
Oncotarget|March 12, 2016
Hypoxia-inducible factor 1 alpha is required for the tumourigenic and aggressive phenotype associated with Rab25 expression in ovarian cancerNatividad Gomez-Roman, Neha Mohan Sahasrabudhe, Fiona McGregor, et al.
International Journal of Cancer|July 11, 2006
Colorectal cancer and genetic polymorphisms of CYP1A1, GSTM1 and GSTT1: a case-control study in the Grampian region of ScotlandJulian Little, Linda Sharp, Lindsey F Masson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 9, 2004
A phase I clinical and pharmacokinetic study of Ro 31-7453 given as a 7- or 14-day oral twice daily schedule every 4 weeks in patients with solid tumorsRamon Salazar, Donald Bissett, Chris Twelves, et al.
The British Journal of Nutrition|December 7, 2007
Polymorphisms in the methylenetetrahydrofolate reductase (MTHFR) gene, intakes of folate and related B vitamins and colorectal cancer: a case-control study in a population with relatively low folate intakeLinda Sharp, Julian Little, Nigel T Brockton, et al.
European Journal of Cancer (Oxford, England : 1990)|July 26, 2008
Open-label, non-randomised, inter-individual dose escalation of ZK 304709 with the evaluation of safety, tolerability, pharmacokinetics, oral bioavailability and orientating efficacy after daily administration in patients with advanced cancer (7 d treatment and 14 d recovery)Janet S Graham, Ruth Plummer, Candice McCoy, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 25, 2010
Disease course patterns after discontinuation of bevacizumab: pooled analysis of randomized phase III trialsDavid Miles, Nadia Harbeck, Bernard Escudier, et al.
Pageof 5

Showing results (21-30 of 49) with videos related to

Sort By:
Pageof 5
Lancet (London, England)|June 28, 2002
Is the NICE process flawed?Jim Cassidy, John Bridgewater, Paul Mainwaring, et al.
Journal of Hazardous Materials|December 7, 2007
Corporate crisis management managing a major crisis in a chemical facilitySteve Marwitz, Neil Maxson, Bill Koch, et al.
Family Practice|July 12, 2002
Striking the right balance in colorectal cancer care--a qualitative study of rural and urban patientsNorma S C Bain, Neil C Campbell, Lewis D Ritchie, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 22, 2005
Significant effect of capecitabine on the pharmacokinetics and pharmacodynamics of warfarin in patients with cancerRoss Camidge, Bruno Reigner, Jim Cassidy, et al.
Oncotarget|March 12, 2016
Hypoxia-inducible factor 1 alpha is required for the tumourigenic and aggressive phenotype associated with Rab25 expression in ovarian cancerNatividad Gomez-Roman, Neha Mohan Sahasrabudhe, Fiona McGregor, et al.
International Journal of Cancer|July 11, 2006
Colorectal cancer and genetic polymorphisms of CYP1A1, GSTM1 and GSTT1: a case-control study in the Grampian region of ScotlandJulian Little, Linda Sharp, Lindsey F Masson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 9, 2004
A phase I clinical and pharmacokinetic study of Ro 31-7453 given as a 7- or 14-day oral twice daily schedule every 4 weeks in patients with solid tumorsRamon Salazar, Donald Bissett, Chris Twelves, et al.
The British Journal of Nutrition|December 7, 2007
Polymorphisms in the methylenetetrahydrofolate reductase (MTHFR) gene, intakes of folate and related B vitamins and colorectal cancer: a case-control study in a population with relatively low folate intakeLinda Sharp, Julian Little, Nigel T Brockton, et al.
European Journal of Cancer (Oxford, England : 1990)|July 26, 2008
Open-label, non-randomised, inter-individual dose escalation of ZK 304709 with the evaluation of safety, tolerability, pharmacokinetics, oral bioavailability and orientating efficacy after daily administration in patients with advanced cancer (7 d treatment and 14 d recovery)Janet S Graham, Ruth Plummer, Candice McCoy, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 25, 2010
Disease course patterns after discontinuation of bevacizumab: pooled analysis of randomized phase III trialsDavid Miles, Nadia Harbeck, Bernard Escudier, et al.
Pageof 5